1. Which of the following is the primary source of plasma for production of intravenous immune globulin (IVIG) therapy:

2. Which of the following would be the MOST beneficial holding period for plasma donations in the IVIG production pipeline:

3. Which of the following standards recommends the hold period for donated plasma prior to manufacturing:

4. Which one of the processes listed below leads to immunoglobulin A (IgA) separation from the immunoglobulin G (IgG) fraction:

5. Which of the following stabilizers is NOT associated with renal complications with IVIG therapy:

6. For which of the following patients would it be advantageous to avoid an IVIG product with a high sodium content and larger volume preparation:

7. When starting a patient on IVIG therapy, which of the following adverse events would be the MOST likely to occur:

8. A patient 45 years of age presents with newly diagnosed CIDP at a local neurologist's office. The treatment plan is to start IVIG therapy. Which of the following treatment doses of IVIG therapy is MOST appropriate:

9. Which of the following products would be an appropriate option for subcutaneous administration for a patient with primary humoral immunodeficiency?

10. Which of the following is an approved U.S. Food and Drug Administration (FDA) indication for IVIG therapy:

« Return to Activity